Periods in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

... of $3.7 million and $9.5 million for the same periods in 2008. Isis' financial results in 2009 reflect ... operations. Accordingly, Isis has presented all periods of Ibis' operating results in Isis' financial ... to $29.7 million and $48.1 million in the same periods of 2008. The substantial increase in Isis' ...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

... of AZ-004." Financial Results - periods Ended June 30, 2008 and 2007 GAAP operating ... million and $28.0 million for the comparable periods in 2007. The increases resulted primarily from ... to $557,000 and $1,276,000 in the comparable periods in 2007. Alexza's Consolidated Statements ...

Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status

... $10.5 million and $36.5 million in the comparable periods in 2006. GAAP operating expenses were $17.4 ... million and $46.5 million for the comparable periods in 2006. The increases resulted from spending on ... to $810,000 and $2,217,000 in the comparable periods in 2006. Alexza's Consolidated Statements of ...

Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results

... $30.3 million, or $1.13 per share, for the same periods in 2006. Research and development expense was ... $7.5 million and $23.4 million for the same periods in 2006. The increases were primarily due to ... $458,000 and $1.4 million for the same periods in 2006. Marketing, general and administrative ...

Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases

... effective doses of medications to the interior of the eye over long periods of time (weeks to months). Currently drops, periocular injections and ... are used to deliver medications to the eye but generally for short periods of time. Dr. Murphree, who is a recipient of a National Institutes ...

Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets

... the colon and rectum and is typically characterized by flares followed by periods of remission. Moderately active UC is characterized by tougher symptoms ... on the extent and severity of disease. UC causes flares followed by periods of remission. During a flare, in which the rectum or colon become ...

PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference

... over 500,000 patients in Europe and North America. Patients suffer periods of flare-ups characterized by intense symptoms, interspersed with periods of relative remission where symptoms decrease or disappear. As Crohn's ...

Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program

... elimination of corticosteroid treatment, and to sustain this for extended periods of time. The NTI-0501 study also showed that XERECEPT(R) therapy was well tolerated over extended periods up to two years or more. "We are delighted to see the results from ...

Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease

... can last several hours per day. At this stage, patients often experience periods of loss of movement control during the day (so-called "off"-time), which alternates with periods of relatively good motor functions (so-called "on"-time). ...

Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus

... vessels, liver, kidneys and nervous system. Lupus is characterized by periods of flares, or exacerbations, interspersed with periods of improvement or remission. It is estimated that between 1.5 - 2 million ...

APTA Supports Surgeon General's 'Call to Action' to Prevent Deep Vein Thrombosis and Pulmonary Embolism

... Section, blood clots, called deep vein thrombosis (DVT), can occur after periods of being immobile, such as on long plane flights. Scherer notes that the ... APTA President Marilyn Moffat, PT, PhD, DPT. "Sitting still for long periods may lead to swelling of the feet, which becomes obvious to many passengers ...

ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease

... affects over 500,000 patients in Europe and North America. Patients suffer periods of flare-ups characterized by intense symptoms, interspersed with periods of relative remission where symptoms decrease or disappear. As Crohn's ...

Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis

... of the American Academy of Neurology (AAN) do not define specific time periods for when treatment should be initiated, patients may be reluctant to begin ... normal and Parkinson movements) and wearing-off complications (shortened periods of benefit after each levodopa use). "Levodopa continues to be the ...

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

... enough steroids) may appear in a small number of patients, particularly when ASMANEX is administered at higher than recommended doses over prolonged periods of time. If such effects occur, consult your health care provider as the dosage of ASMANEX should be reduced slowly. If you or your child ...

Shoulder Surgery Doesn't Prevent Return to Sports

... rest of an individual's life, no matter their age. "Eighty-eight percent of the individuals in our study returned to their activity levels for periods greater than 30 minutes per session with the same type of intensity. It also appears that the most likely reason for returning to the same level of ...

ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients

... enough steroids) may appear in a small number of patients, particularly when ASMANEX is administered at higher than recommended doses over prolonged periods of time. If such effects occur, consult your health care provider as the dosage of ASMANEX should be reduced slowly. If you or your child took ...

New AHRQ Study Finds Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation

... The new comparative effectiveness report found that the procedure has been shown to provide benefits in maintaining normal heart rhythm over short periods of time (up to 1 year) but found little evidence indicating whether the procedure reduces the chance that patients will experience atrial ...

FDA Advisory Committee Votes in Favor of Zyprexa for Two Adolescent Indications

... impairments such as diminished emotion, lack of interest and depressive signs and symptoms(1). Manic symptoms of bipolar I disorder include long periods of euphoria, restlessness, behaving impulsively and being easily distracted(2). A mixed bipolar state occurs when symptoms of depression and mania ...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

... statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop ...

Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW

... biomarker stability over similar time periods. Further studies are required to evaluate the impact of therapy on biomarker stability over longer periods of time. The clinical utility of PROMETHEUS IBD Serology 7 was further demonstrated in a separate, multi-center clinical study of an additional ...

Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction

... statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including our ability to successfully complete the clinical trials required for us ...

New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal

... IR treatment groups showed a statistically significant improvement in pain compared to patients who received placebo, during all of these time periods (P <0.001), achieving both the primary efficacy endpoint of the sum of pain intensity difference (SPID) at 48 hours and secondary efficacy ...

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

... treatment effect on this endpoint was observed at all six assessment periods, including Week 72, in CAPACITY 2, and at all four of the assessment periods through Week 48 in CAPACITY 1, but not at Week 72. An analysis of pooled data from the two CAPACITY studies showed that placebo-treated patients ...

Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status

... and quality systems processes. We continue to target our AZ-004 NDA submission for the first quarter of 2010." Financial Results - periods Ended March 31, 2009 and 2008 GAAP operating expenses were $16.4 million and $19.2 million in the quarters ended March 31, 2009 and 2008, ...

Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes

... therapy, and proprietary formulation technology that maintains stability of therapeutic proteins and peptides at human body temperature for extended periods of time. Exenatide, the active agent in ITCA 650, has been approved in the US, Europe and many other markets and is currently marketed as a ...

DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation

... statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop ...

Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression

... which is characterized by fluctuations between extreme highs (manic) and lows (depressed) in mood. People with bipolar disorders cycle between periods of manic or depressive mood and typically spend more time in the depressed phase of the illness. The eight-week, double-blind, ...

March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots

... history of DVT, and obesity. Any of several situations can trigger deep vein thrombosis. Airplane rides lasting six hours or more and long periods of sitting for any reason pose risks. That's why travelers are urged to stretch or walk every hour and stay well hydrated during long flights. ...

Research Finding Could Revolutionize Asthma Treatment

... these two drugs have the opposite effect of beta blockers. Specifically, they clearly improve asthma in the short run, but if taken for long periods they may actually be harmful. Dr. Bond is a Professor in the Department of Pharmacological and Pharmaceutical Sciences, University of Houston , ...

ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients

... labialis (cold sores), and herpes genitalis (genital herpes). Like other herpes viruses, CMV has the ability to remain dormant in the body for long periods of time. Human CMV infection rates average between 50 percent and 85 percent of adults in the U.S. by 40 years of age, but in healthy adults causes ...

Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial

... endpoint by increasing daily "ON" time in mid- to late-stage Parkinson's disease patients with motor fluctuations by 1.3 hours. "ON" time represents periods when Parkinson's patients experience their best level of motor functioning. The two safinamide treatment groups of the study (receiving ...

American Dairy Provides Business Update

... are continuing, and when they are completed, the Company expects to file reports with the SEC that will include financial statements for the periods that are the subject of the Re-audits, the 2007 fiscal year, and the 2008 fiscal year. About American Dairy, Inc. American Dairy, Inc. ...

Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults

... with older adults, appears to be causing larger numbers of young adults to turn to prescription sleep aids, and to depend on them for longer periods of time," said William Marder, PhD, senior vice president and general manager for the Healthcare business of Thomson Reuters. The study is ...

Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial

... statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including the Company's ability to successfully complete those clinical trials ...

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

... Certain conditions can elevate a person's risk of clotting, including atrial fibrillation (an abnormal heart rhythm), previous heart attack, long periods of inactivity, some medications, and genetic or disease-related factors. Treatment typically consists of anticoagulants that help prevent clots from ...

Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update

... shelf registration in the first quarter of 2008, there is a lack of comparability in the per share amounts between the 2008 and 2007 periods presented. CADENCE PHARMACEUTICALS, INC. (a development stage company) CONDENSED ...

Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium

... San Francisco. "The therapy was well tolerated and demonstrated evidence of clinical activity, with several patients experiencing prolonged periods of disease stabilization following treatment. These findings warrant further study of this promising immunotherapy." The two Phase 1 studies ...

BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease

... is a chronic, lifelong disease that affects a significantly large population of approximately 100,000 people in the U.S. These patients suffer periods of intense pain, poor blood flow, organ damage and other serious medical complications. To date, however, there are very limited treatment options ...

New Studies Highlight Benefits of Coblation(R)-Assisted Procedures in Airway Fire Prevention and Endoscopic Sinus Surgery

... strength of the Company's technology and its continued adoption, unanticipated accounting issues or audit issues regarding the financial data for the periods being restated in the Company's previously announced restatement; the ability of the Company and its independent registered public accounting firm to ...

Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis

... 96-week period of the study will be eligible to enroll in a 96- week long-term follow-up treatment period. These maintenance and long-term follow-up periods of the study are intended to assess the effect of early treatment with Cladribine tablets on relapses and subsequent treatment response to ...